Loopbaan van Helen Jenkins
Eerdere bekende functies van Helen Jenkins
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Operationeel Directeur | 01-01-2007 | 01-01-2011 |
Saegis Pharmaceuticals, Inc.
Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Operationeel Directeur | 01-01-2000 | 01-01-2007 |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Algemeen Directeur | - | - |
TOBIRA THERAPEUTICS INC | Operationeel Directeur | 04-05-2015 | - |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Operationeel Directeur | 11-04-2014 | - |
Corporate Officer/Principal | 01-08-2011 | 11-04-2014 | |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Algemeen Adviseur | 06-06-2011 | - |
Corporate Officer/Principal | - | 07-06-2011 | |
Glycomed, Inc.
Glycomed, Inc. Pharmaceuticals: MajorHealth Technology Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
Opleiding van Helen Jenkins
San Francisco State University | Graduate Degree |
California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 11 |
Operationeel
Chief Operating Officer | 4 |
Corporate Officer/Principal | 4 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 9 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 8 |
---|---|
Saegis Pharmaceuticals, Inc.
Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Health Technology |
Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Glycomed, Inc.
Glycomed, Inc. Pharmaceuticals: MajorHealth Technology Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on September 11, 2006 and is headquartered in Madison, NJ. | Health Technology |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Health Technology |
- Beurs
- Insiders
- Helen Jenkins
- Ervaring